DMK Pharmaceuticals Corporation Common Stock
DMK was delisted on the 6th of February, 2024.
43 hedge funds and large institutions have $2.55M invested in DMK Pharmaceuticals Corporation Common Stock in 2022 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 3 increasing their positions, 8 reducing their positions, and 7 closing their positions.
4,125% more call options, than puts
Call options by funds: $169K | Put options by funds: $4K
4% less funds holding
Funds holding: 45 → 43 (-2)
29% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 7
60% less capital invested
Capital invested by funds: $6.44M → $2.55M (-$3.89M)
63% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$68.9K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$53.8K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$13.9K |
| 4 |
VF
Virtu Financial
New York
|
+$9.57K |
| 5 |
Janney Montgomery Scott
Philadelphia,
Pennsylvania
|
+$3.69K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Creative Planning
Overland Park,
Kansas
|
-$50K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$43K |
| 3 |
TSS
Two Sigma Securities
New York
|
-$19.7K |
| 4 |
HighTower Advisors
Chicago,
Illinois
|
-$14K |
| 5 |
HF
HRT Financial
New York
|
-$13K |
DMK Hedge Fund Activity: Q3 2022 in Review
43 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in DMK Pharmaceuticals Corporation Common Stock (DMK) for Q3 2022, worth a combined $2.55M — down 60% from $6.44M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of DMK and 5 opened new positions — a net loss of 2 holders — while 8 trimmed existing stakes and 3 added.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $68.9K. The largest seller was Creative Planning, exiting entirely with an estimated $50K sold.
- 43 institutional investors held DMK Pharmaceuticals Corporation Common Stock (DMK) as of Q3 2022, down from 45 in Q2 2022.
- Funds reported $2.55M of DMK Pharmaceuticals Corporation Common Stock stock for Q3 2022, down 60% quarter-over-quarter.
- 5 funds opened new DMK Pharmaceuticals Corporation Common Stock positions in Q3 2022 and 7 closed out, a net change of -2 holders.
- The largest DMK Pharmaceuticals Corporation Common Stock buyer in Q3 2022 was Susquehanna International Group, an estimated $68.9K added.
- The largest DMK Pharmaceuticals Corporation Common Stock seller in Q3 2022 was Creative Planning, an estimated $50K sold.
Based on aggregated 13F filings for Q3 2022.